CG Oncology, Inc. is a clinical biopharmaceutical company that focuses on the development and commercialization of bladder-sparing therapies for patients with bladder cancer. The company is headquartered in Irvine, California, and currently has 113 full-time employees. It went public on January 25, 2024. The company's lead product candidate, cretostimogene grenadenorepvec (cretostimogene), is in clinical development for the treatment of non-muscle invasive bladder cancer (NMIBC). BOND-003 is a Phase III clinical trial designed to evaluate the safety and efficacy of cretostimogene as a monotherapy in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC. CORE-001 is a Phase II single-arm, open-label trial investigating cretostimogene in combination with BCG-unresponsive NMIBC. The company's pipeline also includes PIVOT-006, a Phase III trial assessing the safety and efficacy of adjuvant cretostimogene as monotherapy in intermediate-risk NMIBC patients following transurethral resection of bladder tumor (TURBT).
Follow-Up Questions
Who is the CEO of CG Oncology Inc?
Mr. Arthur Kuan is the Chairman of the Board of CG Oncology Inc, joining the firm since 2017.
What is the price performance of CGON stock?
The current price of CGON is $39.07, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CG Oncology Inc?
CG Oncology Inc belongs to Biotechnology industry and the sector is Health Care
What is CG Oncology Inc market cap?
CG Oncology Inc's current market cap is $2.9B
Is CG Oncology Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for CG Oncology Inc, including 3 strong buy, 13 buy, 1 hold, 0 sell, and 3 strong sell
